TY - T1的挑战在多发性硬化诊断:误用和误解的麦当劳标准(S6.001) JF -神经学乔-神经学六世- 92 - 15补充SP - S6.001 AU -安德鲁·所罗门盟-罗马小矮星AU -罗伯特·奈史密斯盟萨利姆Chahin AU -斯蒂芬Krieger盟布莱首页恩Weinshenker Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_Supplement/S6.001.abstract N2 -目的:评估适当的应用程序麦当劳标准的关键元素在神经病学居民和多发性硬化症(MS)专家。背景:研究表明知识缺口识别的典型症状女士,室旁和juxtacortical MRI病灶位置,考虑历史的症状可能会导致误诊。设计/方法:神经病学居民和练习女首页士专家完成了一项网络调查通过电子邮件邀请。结果:72名居民和88 MS专家参加了来自美国和加拿大。女士错误地认定为典型的非典型症状包括:完成横向脊髓病(35%的居民,15%的女士专家),棘手的呕吐恶心/打嗝(20%的居民,5%的女士专家),和双边视神经炎/视觉差的单侧视神经炎恢复(17%的居民,10%的女士专家)。“触摸或对接”的心室标准室周的病变是正确确定38%的居民和61%的女士专家;“juxtacortical”标准是正确确定19%的居民和54%的女士专家。视神经参与错误地认定为是一个地区实现MRI在空间传播(DIS) 31%的居民和26%的女士专家。皮层下白质错误识别出11%的居民和18%的专家作为实现地区核磁共振女士说。放射检查孤立综合症(RIS)病例是错误地分配满足麦当劳标准的48%的居民和12%的女士专家。非特异性历史视觉症状被认为是实现传播时间(说),75%的居民和49%的专家,女士和非特异性症状被认为是实现历史感觉和协调专家女士说了88%的居民和65%。将额外的案例和成像进行响应。结论:女士从一个较小的程度首页上,神经病学的居民和专家错误地确定MS诊断标准的核心组件。教育可能会减少误诊的努力专注于麦当劳的误解和误用的组件标准。Disclosure: Dr. Solomon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Solomon has received research support from Biogen. Dr. Pettigrew has nothing to disclose. Dr. Naismith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, and Novartis. Dr. Naismith has received personal compensation in an editorial capacity as the Associate Editor NEJM Journal Watch. Dr. Naismith has received research support from Acorda, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, and Novartis. Dr. Chahin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme and Teva. Dr. Krieger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Bayer, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Mallinckrodt, MedDay, Novartis, Teva, and TG Therapeutics. Dr. Weinshenker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, MedImmune, Caladrius Biosciences, Brainstorm Therapeutics, Chugai, and Roivant Sciences. Dr. Weinshenker has received royalty, license fees, or contractual rights payments from RSR Ltd, Oxford University, Hospices Civil de Lyon, MVZ Labor PD Dr. Volkmann und Kollegen GbR. ER -